Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The New Economy and its Winners -- Ignore unavailable to you. Want to Upgrade?

To: bob zagorin who wrote (29975)	8/2/2006 10:56:11 PM
From: Bill Harmond	Read Replies (1) \| Respond to of 57684

Well, hoooray... 02-Aug-06 16:44 ET In Play Foxhollow beats by $0.15, guides Q3 EPS above consensus, issues mixed Y06 guidance (24.45 -0.85) : Reports Q2 (Jun) earnings of $0.02 per share, $0.15 better than the Reuters Estimates consensus of ($0.13); revenues rose 67.9% year/year to $48.2 mln vs the $47.5 mln consensus. Co issues upside guidance for Q3, sees EPS of $0.10-0.15 vs. $0.05 consensus; sees Q3 revs of $53-55 mln vs. $54.23 mln consensus. Co issues mixed guidance for FY06, sees EPS of loss of $0.07-0.22 vs. -$0.06 consensus; sees FY06 revs of $210-214 mln vs. $211.82 mln consensus. Briefing.com Note: EPS Estimates, actuals and guidance are all on GAAP basis and include stock based compensation expense. 02-Aug-06 17:42 ET In Play Foxhollow--Conference Call Summary (24.45 ) -Update : Co's downward guidance for 06 EPS seems to be due to delays launching the "Rockhawk" product. Product launch will now take place in early 07. Turbohawk product is on schedule for launch in late '07 . Co's primary product, Silverhawk, is the market leader in arterial plaque excision. Co's main focus is on expanding market share and entrenching their product line in arterial surgical and pseudo-surgical applications by developing a marketing platform of expanded indications and applications for the Silverhawk and new, closely related "cousin" products. Notable here is the "Nighthawk", which allows physicians to go into the excision region with real-time, on-board internal imaging. This product should be available for initial use by year-end, and should head into formal commercialization in Q3 2007. Clinical trials for several other product expansions in the "Hawk" line are well underway. Key detail of call: Co says that, in addition to collaborative deal with Merck, co is in the formative stages of "several other deals" which should contribute to revenues before the end of the year. Co stated they would comment no further on these deals until a future press release. Stock is trading at 27.40 after market. Trading has gone as high as 29.70, up over 21% from the close of regular trading hours.